What is indicated by a Complete Response (CR) Letter from the FDA?

A Complete Response (CR) Letter from the FDA indicates that the application will be rejected in its current form. This type of letter is issued when the FDA has completed its review of a drug application and determined that it cannot be approved in its present state due to identified deficiencies.

The CR letter outlines the specific issues that need to be addressed before the application can be reconsidered for approval. These issues may relate to the drug's safety, efficacy, labeling, or other factors important to the regulatory evaluation. The issuance of a CR letter signals that the application requires substantial work or data submission before the FDA will consider approval.

Understanding the implications of a CR letter is crucial for pharmaceutical companies, as it mobilizes a response to address the concerns highlighted by the FDA, leading to potential re-submission in the future.